Home Overview Press Room Blog Publications For Students about us

Biotech & Pharma : Displaying 747-756 of 1641

A Dangerous Game: Some Athletes Risk Untested Stem Cell Treatments by Deborah FranklinScientific AmericanJanuary 16th, 2013Some professional athletes' enthusiasm for certain stem cell treatments outpaces the evidence.
IVF on Steroids: The Dangerous Off-Label Use of 'Dex' During Pregnancyby Alice DregerThe AtlanticJanuary 16th, 2013Fertility clinics across the U.S. are prescribing a medication with a seriously concerning safety profile and no proven benefits.
The Case for Paternalism in Genetic Testingby Laura HercherWiredJanuary 14th, 2013In light of recent articles arguing for more openness and less worry about people receiving their genomic information, one genetic counselor explains why she cannot participate in the full-throated enthusiasm.
A Rebuttal to Mark Lynasí GMO Reversalby Jason MarkEarth Island JournalJanuary 11th, 2013Organic farmer, writer, and environmental policy advocate delves into Lynas' rationale for turning pro-GMO and finds scientific, environmental, economic, and social reasons not to agree.
Eric Hoffman on a Very Discreet Newcomer: Synthetic Biologyby Eric HoffmanA World of ScienceJanuary 11th, 2013An interview on the dangers of synthetic biology published in UNESCO's Natural Sciences Sector's quarterly journal.
New York Examines Over 800 Rape Cases for Possible Mishandling of Evidenceby Joseph GoldsteinThe New York TimesJanuary 10th, 2013The review underscores that DNA evidence, widely perceived as providing nearly irrefutable proof of guilt or innocence, is subject to human error.
Safety of Induced Stem Cells Gets a Boostby Monya BakerNatureJanuary 9th, 2013A new paper could renew hopes of turning a patientís own cells into perfectly matched replacement tissues, though differences in methodology between the study and clinical practice have left some eager for more proof.
Your Medical Data in the Cloud? Not So Fast, Says HHS Privacy Officialby Andrea PetersonScience ProgressJanuary 9th, 2013Digital health records are superior to physical ones for many reasons, but data security and privacy of health information are major obstacles and policy has not yet caught up with practice.
No Easy Answer[Editorial]NatureJanuary 9th, 2013Demands to analyse the DNA of the Connecticut school shooter are misguided and could lead to dangerous stigmatization, or worse.
Follow the Biotech Money Ö If You Can Find It by Pete ShanksBiopolitical TimesJanuary 9th, 2013In a relatively slow period for mergers and acquisitions in genomics and related sectors, Illumina, Amgen, BGI, and BioTime were buyers and 23andMe added financing while Geron sold and Roche held off.
Displaying 747-756 of 1641  
< Prev  Next >> 
« First Page Last Page » 
« Show Complete List » 


home | overview | blog | publications| about us | donate | newsletter | press room | privacy policy

CGS • 1936 University Ave, Suite 350, Berkeley, CA 94704 • • (p) 1.510.665.7760 • (F) 1.510.665.8760